MX2019003837A - Composición que comprende una combinación del análogo de tirotropina (trh) con ácido arúndico, y la sal farmacéuticamente aceptable del acido arúndico. - Google Patents

Composición que comprende una combinación del análogo de tirotropina (trh) con ácido arúndico, y la sal farmacéuticamente aceptable del acido arúndico.

Info

Publication number
MX2019003837A
MX2019003837A MX2019003837A MX2019003837A MX2019003837A MX 2019003837 A MX2019003837 A MX 2019003837A MX 2019003837 A MX2019003837 A MX 2019003837A MX 2019003837 A MX2019003837 A MX 2019003837A MX 2019003837 A MX2019003837 A MX 2019003837A
Authority
MX
Mexico
Prior art keywords
composition
arundic acid
combination
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MX2019003837A
Other languages
English (en)
Inventor
Yamamura Michio
Tateishi Narito
Original Assignee
Brivention Pharmaceutical Shanghai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brivention Pharmaceutical Shanghai Inc filed Critical Brivention Pharmaceutical Shanghai Inc
Publication of MX2019003837A publication Critical patent/MX2019003837A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/126—Acids containing more than four carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/126—Acids containing more than four carbon atoms
    • C07C53/128—Acids containing more than four carbon atoms the carboxylic group being bound to a carbon atom bound to at least two other carbon atoms, e.g. neo-acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/30—Other Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un objetivo de esta invención es proporcionar una composición para la prevención y/o tratamiento de enfermedades neurodegenerativas e infarto cerebral, y una composición para mejorar los trastornos de aprendizaje; se proporciona una composición 5 que comprende una combinación de un análogo de TRH y ácido arundico.
MX2019003837A 2016-10-03 2017-09-27 Composición que comprende una combinación del análogo de tirotropina (trh) con ácido arúndico, y la sal farmacéuticamente aceptable del acido arúndico. MX2019003837A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016195505 2016-10-03
JP2017184731 2017-09-26
PCT/JP2017/034926 WO2018066427A1 (ja) 2016-10-03 2017-09-27 Ｔｒｈアナログ及びアルンド酸を組み合わせてなる組成物、並びにアルンド酸の薬学的に許容される塩

Publications (1)

Publication Number Publication Date
MX2019003837A true MX2019003837A (es) 2019-06-24

Family

ID=61832036

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003837A MX2019003837A (es) 2016-10-03 2017-09-27 Composición que comprende una combinación del análogo de tirotropina (trh) con ácido arúndico, y la sal farmacéuticamente aceptable del acido arúndico.

Country Status (16)

Country Link
US (1) US10828303B2 (es)
EP (1) EP3520795B1 (es)
JP (2) JP6596697B2 (es)
KR (1) KR20190065315A (es)
CN (2) CN113559102B (es)
AU (1) AU2017340594B2 (es)
BR (1) BR112019006429A2 (es)
CA (1) CA3039027A1 (es)
CO (1) CO2019003255A2 (es)
IL (1) IL265688A (es)
MX (1) MX2019003837A (es)
PH (1) PH12019500636A1 (es)
SG (1) SG11201902599SA (es)
TW (1) TW201818939A (es)
WO (1) WO2018066427A1 (es)
ZA (1) ZA201902341B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907591D0 (en) * 2019-05-29 2019-07-10 Eolas Res Limited Composition and use
IT202000015895A1 (it) 2020-07-27 2022-01-27 Univ Cattolica Del Sacro Cuore L’impiego di acido arundico nella terapia della sclerosi multipla

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6223429A (ja) * 1985-07-24 1987-01-31 Ishikawajima Harima Heavy Ind Co Ltd 水素同位体の回収・貯蔵・供給装置
JPS62234029A (ja) * 1985-12-27 1987-10-14 Tanabe Seiyaku Co Ltd 中枢神経賦活剤
DK0632008T3 (da) 1993-06-01 1998-09-23 Ono Pharmaceutical Co Pentansyrederivater
JPH0782166A (ja) 1993-09-14 1995-03-28 Tanabe Seiyaku Co Ltd 抗ショック剤
US9016221B2 (en) * 2004-02-17 2015-04-28 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
JP4730303B2 (ja) 2004-04-28 2011-07-20 小野薬品工業株式会社 （２ｒ）−２−プロピルオクタン酸とアミンとからなる結晶
JP2006143708A (ja) * 2004-10-19 2006-06-08 Ono Pharmaceut Co Ltd 神経変性疾患治療用医薬
TW202021946A (zh) * 2008-05-23 2020-06-16 美商派洛泰克藥物股份有限公司 四環素化合物之甲苯磺酸鹽及同素異形體
SG176295A1 (en) * 2009-06-16 2012-01-30 Cardoz Ab Crystalline form of pemirolast
CN102786414B (zh) * 2012-08-15 2014-07-16 四川大学 一类用于治疗和/或预防神经退行性相关疾病的化合物

Also Published As

Publication number Publication date
EP3520795B1 (en) 2023-06-14
CN113559102A (zh) 2021-10-29
CO2019003255A2 (es) 2019-04-12
JP2019203007A (ja) 2019-11-28
CN110267661B (zh) 2021-08-03
US20190240221A1 (en) 2019-08-08
JPWO2018066427A1 (ja) 2019-07-25
EP3520795A1 (en) 2019-08-07
TW201818939A (zh) 2018-06-01
CN113559102B (zh) 2023-01-03
AU2017340594B2 (en) 2020-09-10
CA3039027A1 (en) 2018-04-12
BR112019006429A2 (pt) 2019-06-25
PH12019500636A1 (en) 2019-10-28
CN110267661A (zh) 2019-09-20
SG11201902599SA (en) 2019-05-30
KR20190065315A (ko) 2019-06-11
JP6596697B2 (ja) 2019-10-30
AU2017340594A1 (en) 2019-04-18
ZA201902341B (en) 2020-08-26
WO2018066427A1 (ja) 2018-04-12
IL265688A (en) 2019-05-30
NZ752311A (en) 2020-12-18
US10828303B2 (en) 2020-11-10
EP3520795A4 (en) 2020-05-13

Similar Documents

Publication Publication Date Title
IL271085A (en) Bacteria to treat disorders
IL298690B1 (en) Preparations and methods for suppressing masp-3 for the treatment of various diseases and conditions
MD3804737T2 (ro) Compoziții care conțin tulpini bacteriene
EP4353324A3 (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
MX2018008105A (es) Compuestos inhibidores de metaloenzima.
EP3600349A4 (en) Colon selective sequestrants for the treatment and prevention of autism and allied diseases
EP3507371A4 (en) METHODS AND COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM
ZA201805407B (en) Composition for the prevention or treatment of neurodegenerative diseases.
GB202019418D0 (en) Novel therapeutics for the treatment of neurodegenerative disorders
IL263477A (en) Compositions and methods for the treatment or prevention of oxalate-related disorders
IL288001A (en) Compounds for the treatment of neurodegenerative and metabolic disorders
ZA202002993B (en) Compounds for the treatment of neuromuscular disorders
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
PH12019500636A1 (en) Composition comprising combination of trh analog with arundic acid, and pharmaceutically acceptable salt of arundic acid
ZA202003243B (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
IL272097A (en) Compounds for the prevention and treatment of medical disorders and their uses
EP3600324A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISORDERS
EP3131635A4 (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
EP3568138A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ILLNESSES OR DISORDERS ASSOCIATED WITH MYELIN AND INFLAMMATION
EP3534924A4 (en) COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF HEART CIRCULAR DISEASES
PT3752173T (pt) Combinação de rhodiola e de astragalus para o tratamento de doenças neurodegenerativas.
EP3838272A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASE
EP3532081C0 (en) COMPOSITION FOR THE PREVENTIVE OR CURATIVE TREATMENT OF HEPATIC DISORDERS
BR112018012343A2 (pt) composições de benzofenonas poli-hidroxiladas e métodos de tratamento de distúrbios neurodegenerativos